Startup entity
market-trends is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention BioFlorida, the most common co-covered peer. At 5, the average consequence score sits below the same-window beat average of 6.3.
Last mentioned: Mar 10, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
market-trends is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention BioFlorida, the most common co-covered peer. At 5, the average consequence score sits below the same-window beat average of 6.3. They are less corroborated than the beat average, carrying 2 original sources each against 2.3 for the same window. NMIIA/IIB inhibitor appears in 1 tracked Startup story from March 10, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 34 Startup stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering NMIIA/IIB inhibitor. Shared-story counts are live from our verified record — not editorial picks.
Clinical Milestones
Anticipated updates on Phase 1/2 glioblastoma trial progress.
BioFlorida Showcase
Cornerstone Session presentation on Innovation in South Florida.
Investival Showcase
Presentation at the South Florida Rising Life Science Hub event.
National Engagement
Presented at BioCom California and BIO Investor Forum to engage global partners.
Myosin Therapeutics has been selected to present its novel nanomotor-dependency platform at two major South Florida life sciences conferences this March. The company is advancing MT-125, a first-in-class inhibitor currently in Phase 1/2 trials for glioblastoma, as it seeks to capitalize on South Florida's emergence as a biotechnology hub.
NMIIA/IIB inhibitor is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
